Influence of co-trimoxazole on methotrexate pharmacokinetics in children with acute lymphoblastic leukemia.
The effect of co-trimoxazole on methotrexate (MTX) pharmacokinetics was studied in seven children with ALL in remission receiving weekly maintenance therapy. Each child received MTX alone during one course, and MTX with co-trimoxazole during the next. Co-trimoxazole did not cause any significant alteration in either intestinal absorption of MTX, the degree of MTX plasma protein binding, or the average concentration X time exposure to MTX. These results indicate that low doses of co-trimoxazole do not perturb the serum pharmacokinetics of MTX. However, interaction of these drugs at the cellular level still remains a distinct possibility.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations / Q000494:pharmacology; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D007700:Kinetics; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008727:Methotrexate / Q000378:metabolism* / Q000627:therapeutic use; D011485:Protein Binding / Q000187:drug effects; D011863:Radioimmunoassay; D013420:Sulfamethoxazole / Q000494:pharmacology*; D014295:Trimethoprim / Q000494:pharmacology*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole; D008727:Methotrexate